Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
EdiGene is a Chinese biotechnology company. Its official website serves primarily as a corporate and R&D pipeline showcase. Founded in 2015 and based in the Zhongguancun Life Science Park in Beijing, the company focuses on original innovation in gene editing and its therapeutic translation. Its goal is to develop transformative therapies for major unmet medical needs, including cancer, neuromuscular diseases, autoimmune disorders, and genetic diseases.
The website highlights two main technology platforms: the LEAPER in vivo RNA base editing platform, and the MAGIC immune-compatible / allogeneic cell therapy platform. It also discloses the company’s product pipeline, including allogeneic CAR-T programs for relapsed/refractory non-Hodgkin B-cell lymphoma, autoimmune diseases, and solid tumors, as well as in vivo RNA editing therapies for DMD, Usher syndrome type II, AATD, and other indications. The site also provides company information, scientific founder profiles, publications and reports, press releases, media coverage, recruitment information, and business development contact details.
This is not a standard SaaS or consumer healthcare platform, and it does not publish pricing, subscription plans, or online payment options. Its business model is more likely centered on innovative drug R&D, clinical translation, technology licensing, joint development, and industry partnerships. Specific costs and partnership terms would need to be discussed via the company’s business contact email.
The main advantages are its clearly defined technology strategy and platform-based layout around gene editing, RNA editing, and allogeneic cell therapy. The website discloses the company’s development history, clinical progress, and partnership events, which helps industry stakeholders evaluate it. The availability of both Chinese and English entry points also supports international communication. The drawbacks are that information for general patients is limited, with little practical content such as clinical trial eligibility, treatment accessibility, or patient guidance. In addition, R&D-stage biopharma programs typically have long development cycles, and clinical efficacy, safety, and regulatory approval outcomes remain uncertain.
EdiGene’s website is best suited for pharma BD teams, research institutions, hospital-based clinical research teams, life science investors, and job seekers interested in gene editing and cell therapy. General patients can use it to understand the company’s focus, but should not treat it as a direct channel for diagnosis, treatment, or purchasing medication.
The site’s ICP filing information indicates that it is operated by a Chinese company. Its Chinese-language content is complete, and it is generally directly accessible from mainland China.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on edigene.com official site.
edigene.com is an China Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach edigene.com directly.